Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

SWOG phase II study of safety and efficacy of rhIL-4 in malignant melanoma

Jan. 25, 1999

Polish authorities allow phase II testing of Multikine

Jan. 15, 1999

Health Canada approves new indication for Proleukin

Jan. 12, 1999

Proleukin receives orphan drug status for two new indications

Jan. 7, 1999

Anticancer immunotoxin available for licensing from NIH

Jan. 4, 1999

Promising phase III trial results presented for Coulter's lead cancer therapy

Dec. 29, 1998

Merck obtains option to expand MDX-447 collaboration with Medarex

Dec. 29, 1998

FDA grants fast track designation for OvaRex MAb

Dec. 22, 1998

Cell Genesys and Japan Tobacco enter worldwide collaboration for GVAX cancer vaccine

Dec. 22, 1998

Dendreon presents phase I/II data on APC-8020 at ASH meeting

Dec. 16, 1998

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...